SPI Healthcare
3.517,95
PKT
+1,24
PKT
+0,04
%
Werbung
Analysen zu SPI Healthcare-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 10.02.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 09.02.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 07.02.23 | Roche Neutral | UBS AG | |
| 07.02.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 07.02.23 | Novartis Sell | Deutsche Bank AG | |
| 06.02.23 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 06.02.23 | Roche Sell | Deutsche Bank AG | |
| 03.02.23 | Roche Outperform | Credit Suisse Group | |
| 03.02.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 03.02.23 | Roche Sell | Deutsche Bank AG | |
| 02.02.23 | Roche Hold | Jefferies & Company Inc. | |
| 02.02.23 | Novartis Underperform | Credit Suisse Group | |
| 02.02.23 | Novartis Sell | Deutsche Bank AG | |
| 02.02.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.02.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 01.02.23 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.02.23 | Novartis Buy | Jefferies & Company Inc. | |
| 01.02.23 | Novartis Neutral | UBS AG | |
| 30.01.23 | Roche Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 25.01.23 | Roche Overweight | Barclays Capital | |
| 25.01.23 | Novartis Underweight | Barclays Capital | |
| 24.01.23 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.01.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 20.01.23 | Roche Neutral | UBS AG | |
| 19.01.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 19.01.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 19.01.23 | Roche Sell | Deutsche Bank AG | |
| 09.01.23 | Roche Neutral | UBS AG | |
| 09.01.23 | Novartis Neutral | UBS AG | |
| 06.01.23 | Roche Outperform | Credit Suisse Group | |
| 06.01.23 | Novartis Underperform | Credit Suisse Group | |
| 06.01.23 | Novartis Underweight | Morgan Stanley | |
| 05.01.23 | Novartis Buy | Jefferies & Company Inc. | |
| 05.01.23 | Roche Hold | Jefferies & Company Inc. | |
| 03.01.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 03.01.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 23.12.22 | Novartis Underweight | Barclays Capital | |
| 23.12.22 | Roche Overweight | Barclays Capital | |
| 14.12.22 | Novartis Neutral | UBS AG | |
| 14.12.22 | Roche Neutral | UBS AG |